Cepharanthine synergistically promotes methylprednisolone pharmacodynamics against human peripheral blood mononuclear cells possibly via regulation of P-glycoprotein/glucocorticoid receptor translocation.
Cepharanthine
Glucocorticoid receptor
Methylprednisolone
P-glycoprotein
peripheral blood mononuclear cell
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
11 May 2024
11 May 2024
Historique:
received:
18
10
2023
accepted:
02
05
2024
medline:
12
5
2024
pubmed:
12
5
2024
entrez:
11
5
2024
Statut:
epublish
Résumé
Cepharanthin Peripheral blood mononuclear cells (PBMCs), T lymphocytic leukemia MOLT-4 cells and daunorubicin resistant MOLT-4 cells (MOLT-4/DNR) were used to evaluate the pharmacodynamics and molecular mechanisms. Drug pharmacodynamics was evaluated by WST-8 assay. P-glycoprotein function was examined by rhodamine 123 assay. CD4 CEP synergistically increased methylprednisolone (MP) efficacy with the suppressive effect on the cell viability of PBMCs. 0.3 and 1 μM of CEP significantly inhibited P-glycoprotein efflux function of CD4 CEP synergistically promoted MP pharmacodynamics to decrease the cell viability of the mitogen-activated PBMCs, possibly via inhibiting P-glycoprotein function and potentiating GC receptor translocation. The present study provides new evidence of the therapeutic effect of Cepharanthin
Sections du résumé
BACKGROUND
BACKGROUND
Cepharanthin
METHODS
METHODS
Peripheral blood mononuclear cells (PBMCs), T lymphocytic leukemia MOLT-4 cells and daunorubicin resistant MOLT-4 cells (MOLT-4/DNR) were used to evaluate the pharmacodynamics and molecular mechanisms. Drug pharmacodynamics was evaluated by WST-8 assay. P-glycoprotein function was examined by rhodamine 123 assay. CD4
RESULTS
RESULTS
CEP synergistically increased methylprednisolone (MP) efficacy with the suppressive effect on the cell viability of PBMCs. 0.3 and 1 μM of CEP significantly inhibited P-glycoprotein efflux function of CD4
CONCLUSIONS
CONCLUSIONS
CEP synergistically promoted MP pharmacodynamics to decrease the cell viability of the mitogen-activated PBMCs, possibly via inhibiting P-glycoprotein function and potentiating GC receptor translocation. The present study provides new evidence of the therapeutic effect of Cepharanthin
Identifiants
pubmed: 38734604
doi: 10.1186/s12906-024-04489-z
pii: 10.1186/s12906-024-04489-z
doi:
Substances chimiques
Benzylisoquinolines
0
cepharanthine
7592YJ0J6T
ATP Binding Cassette Transporter, Subfamily B, Member 1
0
Methylprednisolone
X4W7ZR7023
Receptors, Glucocorticoid
0
Benzodioxoles
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
186Subventions
Organisme : the Natural Science Foundation of Hubei Province
ID : 2021CFB244
Organisme : 2023-2024 Annual Scientific Research Project of Traditional Chinese Medicine from Hubei Provincial Administration of Traditional Chinese Medicine
ID : ZY2023Z002
Organisme : Dawn Program of Wuhan Knowledge Innovation Project
ID : 2017816
Organisme : the State Scholarship Fund of China Scholarship Council
ID : 201808420024
Organisme : National Natural Science Foundation of China
ID : 82074395
Informations de copyright
© 2024. The Author(s).
Références
Saito N, Takemori N, Hirai K, Onodera R, Watanabe S, Kohgo Y. High-dose biscoclaurine alkaloids together with prednisolone raise platelet counts in chronic idiopathic thrombocytopenic purpura. Am J Hematol. 1996;51(2):173–4.
pubmed: 8579066
Bailly C. Cepharanthine: An update of its mode of action, pharmacological properties and medical applications. Phytomedicine. 2019;62:152956.
doi: 10.1016/j.phymed.2019.152956
pubmed: 31132753
pmcid: 7126782
Rogosnitzky M, Danks R. Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions. Pharmacol Rep. 2011;63(2):337–47.
doi: 10.1016/S1734-1140(11)70500-X
pubmed: 21602589
Sogawa N, Hirai K, Sogawa C, Ohyama K, Miyazaki I, Tsukamoto G, Asanuma M, Sasaki A, Kitayama S. Protective effect of cepharanthin on cisplatin-induced renal toxicity through metallothionein expression. Life Sci. 2013;92(12):727–32.
doi: 10.1016/j.lfs.2013.01.031
pubmed: 23399700
Semple JW, Provan D. The immunopathogenesis of immune thrombocytopenia: T cells still take center-stage. Curr Opin Hematol. 2012;19(5):357–62.
doi: 10.1097/MOH.0b013e3283567541
pubmed: 22759631
Sandal R, Mishra K, Jandial A, Sahu KK, Siddiqui AD. Update on diagnosis and treatment of immune thrombocytopenia. Expert Rev Clin Pharmacol. 2021;14(5):553–68.
doi: 10.1080/17512433.2021.1903315
pubmed: 33724124
Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829–35.
doi: 10.1182/blood-2017-03-754119
pubmed: 28416506
pmcid: 5813736
Yamazaki T, Shibuya A, Ishii S, Miura N, Ohtake A, Sasaki N, Araki R, Ota Y, Fujiwara M, Miyajima Y, et al. High-dose Cepharanthin for pediatric chronic immune thrombocytopenia in Japan. Pediatr Int. 2017;59(3):303–8.
doi: 10.1111/ped.13151
pubmed: 27596055
Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–207.
doi: 10.1182/blood-2010-08-302984
pubmed: 21325604
Samson M, Fraser W, Lebowitz D. Treatments for primary immune thrombocytopenia: a review. Cureus. 2019;11(10):e5849.
pubmed: 31754584
pmcid: 6830854
García-Carrasco M, Mendoza-Pinto C, Macias Díaz S, Vera-Recabarren M, Vázquez de Lara L, Méndez Martínez S, Soto-Santillán P, González-Ramírez R, Ruiz-Arguelles A. P-glycoprotein in autoimmune rheumatic diseases. Autoimmun Rev. 2015;14(7):594–600.
doi: 10.1016/j.autrev.2015.02.006
pubmed: 25712147
Liu W, Li H, Zhang D, Lv M, Li Y, Hao Y, Chen Y, Liu X, Xue F, Zhang L, et al. Effects of the multidrug resistance-1 gene on drug resistance in primary immune thrombocytopenia. Autoimmunity. 2016;49(7):486–95.
doi: 10.1080/08916934.2016.1191476
pubmed: 27258931
Xu W, Chen S, Wang X, Wu H, Yamada H, Hirano T. Bisbenzylisoquinoline alkaloids and P-glycoprotein function: a structure activity relationship study. Bioorg Med Chem. 2020;28(12):115553.
doi: 10.1016/j.bmc.2020.115553
pubmed: 32503690
Xu W, Meng K, Wu H, Miura T, Suzuki S, Chiyotanda M, Tanaka S, Sugiyama K, Kawashima H, Hirano T. Vitamin K(2) immunosuppressive effect on pediatric patients with atopic dermatitis. Pediatr Int. 2019;61(12):1188–95.
doi: 10.1111/ped.14014
pubmed: 31560147
Xu W, Meng K, Kusano J, Matsuda H, Hara Y, Fujii Y, Suzuki S, Ando E, Wang X, Tu Y, et al. Immunosuppressive efficacy of tetrandrine combined with methylprednisolone against mitogen-activated peripheral blood mononuclear cells of haemodialysis patients. Clin Exp Pharmacol Physiol. 2017;44(9):924–31.
doi: 10.1111/1440-1681.12797
pubmed: 28613399
Xu W, Meng K, Tu Y, Tanaka S, Onda K, Sugiyama K, Hirano T, Yamada H. Tetrandrine potentiates the glucocorticoid pharmacodynamics via inhibiting P-glycoprotein and mitogen-activated protein kinase in mitogen-activated human peripheral blood mononuclear cells. Eur J Pharmacol. 2017;807:102–8.
doi: 10.1016/j.ejphar.2017.04.007
pubmed: 28408143
Xu W, Wang X, Tu Y, Masaki H, Tanaka S, Onda K, Sugiyama K, Yamada H, Hirano T. Plant-derived alkaloid sinomenine potentiates glucocorticoid pharmacodynamics in mitogen-activated human peripheral blood mononuclear cells by regulating the translocation of glucocorticoid receptor. Phytother Res. 2019;33(1):187–96.
doi: 10.1002/ptr.6215
pubmed: 30357956
Xu W, Wang X, Chen S, Wu H, Tanaka S, Onda K, Sugiyama K, Yamada H, Hirano T. Tetrandrine enhances glucocorticoid receptor translocation possibly via inhibition of P-glycoprotein in daunorubicin-resistant human T lymphoblastoid leukemia cells. Eur J Pharmacol. 2020;881:173232.
doi: 10.1016/j.ejphar.2020.173232
pubmed: 32525004
Kobayashi M, Katayama T, Ochiai S, Yoshida M, Kaito K, Masuoka H, Shimada T, Nishiwaki K, Sakai O. High-dose cepharanthin therapy of idiopathic thrombocytopenic purpura. Rinsho Ketsueki. 1992;33(3):405–7.
pubmed: 1578648
Leonard WJ, Donlon TA, Lebo RV, Greene WC. Localization of the gene encoding the human interleukin-2 receptor on chromosome 10. Science. 1985;228(4707):1547–9.
doi: 10.1126/science.3925551
pubmed: 3925551
Kostic M, Zivkovic N, Cvetanovic A, Marjanović G. CD4(+) T cell phenotypes in the pathogenesis of immune thrombocytopenia. Cell Immunol. 2020;351:104096.
doi: 10.1016/j.cellimm.2020.104096
pubmed: 32199587
Huang Z, Yang B, Shi Y, Cai B, Li Y, Feng W, Fu Y, Luo L, Wang L. Anti-TNF-α therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis. Cell Immunol. 2012;279(1):25–9.
doi: 10.1016/j.cellimm.2012.09.001
pubmed: 23059810
Liu K, Hong B, Wang S, Lou F, You Y, Hu R, Shafqat A, Fan H, Tong Y. Pharmacological activity of cepharanthine. Molecules. 2023;28(13):5019.
doi: 10.3390/molecules28135019
pubmed: 37446681
pmcid: 10343550
Liang D, Li Q, Du L, Dou G. Pharmacological effects and clinical prospects of cepharanthine. Molecules. 2022;27(24):8933.
doi: 10.3390/molecules27248933
pubmed: 36558061
pmcid: 9782661
Leng L, Xu Z, Hong B, Zhao B, Tian Y, Wang C, Yang L, Zou Z, Li L, Liu K, et al. Cepharanthine analogs mining and genomes of Stephania accelerate anti-coronavirus drug discovery. Nat Commun. 2024;15(1):1537.
doi: 10.1038/s41467-024-45690-5
pubmed: 38378731
pmcid: 10879537
Xu W, Wang X, Tu Y, Masaki H, Tanaka S, Onda K, Sugiyama K, Yamada H, Hirano T. Tetrandrine and cepharanthine induce apoptosis through caspase cascade regulation, cell cycle arrest, MAPK activation and PI3K/Akt/mTOR signal modification in glucocorticoid resistant human leukemia Jurkat T cells. Chem Biol Interact. 2019;310:108726.
doi: 10.1016/j.cbi.2019.108726
pubmed: 31255635
Xu W, Chen S, Wang X, Tanaka S, Onda K, Sugiyama K, Yamada H, Hirano T. Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases. Pharmacol Ther. 2021;217:107659.
doi: 10.1016/j.pharmthera.2020.107659
pubmed: 32800789